Core Viewpoint - 基石药业-B (02616.HK) reported a significant decline in revenue for the six months ending June 30, 2025, with a decrease of 80.5% year-on-year, primarily due to reduced sales of its drugs and a lack of major licensing agreements [1] Financial Performance - Revenue decreased from RMB 254.2 million to RMB 49.4 million, a drop of RMB 204.8 million [1] - Revenue components included drug sales of RMB 20.2 million, licensing fee income of RMB 17.9 million, and royalties from Shugli monoclonal antibody of RMB 11.3 million [1] - The loss for the period was RMB 270.2 million, compared to a profit of RMB 15.7 million in the same period last year, marking an increase in loss of RMB 285.9 million [1] Drug Sales and Licensing - Sales of the drug普拉替尼 (Pralsetinib) saw a significant decline, attributed to price adjustments and one-time channel compensation in preparation for national health insurance negotiations [1] - The company anticipates that if普拉替尼 is included in the national health insurance directory, the sales growth from 2026 onwards will offset the short-term negative impact on revenue [1] - Licensing fee income also saw a substantial decrease, mainly due to a one-time milestone payment received in the first half of 2024 for the approval of Shugli monoclonal antibody for gastric cancer in China [1] - In July 2025, the company entered into a significant external licensing agreement with Istituto Gentili, expected to generate licensing fee income in the second half of 2025 [1]
基石药业-B(02616.HK)中期大幅亏损2.7亿元